[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000378:metabolism* / Q000627:therapeutic use
D005641:Tegafur; D005472:Fluorouracil